GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Long-Term Debt

Firebrick Pharma (ASX:FRE) Long-Term Debt : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Long-Term Debt?

Firebrick Pharma's Long-Term Debt for the quarter that ended in Dec. 2024 was A$0.00 Mil.

Firebrick Pharma Long-Term Debt Historical Data

The historical data trend for Firebrick Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Long-Term Debt Chart

Firebrick Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Long-Term Debt
- - - -

Firebrick Pharma Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Long-Term Debt Get a 7-Day Free Trial - - - - -

Firebrick Pharma  (ASX:FRE) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Firebrick Pharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Long-Term Debt
Comparable Companies
ASX:ECS ASX:AGH ASX:PER ASX:CAN ASX:RGT ASX:EOF ASX:IVX ASX:EXL ASX:BP8 ASX:NXS LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE
Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Website
https://www.firebrickpharma.com
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines